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Hypogonadism in Men With Chronic Pain Linked to the Use
of Long-acting Rather Than Short-acting Opioids
Andrea L. Rubinstein, MD,* Diane M. Carpenter, MPH,w and Jerome R. Minkoff, MDz
Aim: There is a need to elucidate the variables associated with
testosterone suppression among men on daily opioid therapy for
chronic pain.
Objective: The objective of this study was to examine several var-
iables related to opioid use including daily dose, duration of action
(long acting vs. short acting), and specific opioid to ascertain spe-
cific influences on total serum testosterone levels in men with
chronic pain who use opioids daily.
Setting: This is a retrospective cohort study of men within the
Kaiser Permanente, Northern California (KPNC) health care sys-
tem on some form of daily opioid use for chronic pain.
Participants: Eighty-one men between the age of 26 and 79 years
were seen in a chronic pain clinic between January 2009 and June
2010. All men were on stable dose of an opioid for at least 3
months, none with a previous diagnosis of hypogonadism.
Main Outcome Measures: Total serum AM testosterone levels were
measured at KPNC Regional Laboratory.
Results: Average total serum AM testosterone levels for this pop-
ulation showed 53% of all men receiving daily opioids were
hypogonadal (AM total serum testosterone <250ng/dL). In men
receiving long-acting opioids, 74% (34/46) were hypogonadal
compared with 34% (12/35) in men using short-acting opioids
(hydrocodone or oxycodone) exclusively [AM total testosterone:
median, 126 ng/dL; mean, 169 ng/dL (SD, 128 ng/dL) vs. median,
283 ng/dL; mean, 315 ng/dL (SD, 142 ng/dL); P<0.001]. After
controlling for daily dosage and body mass index, men on long-
acting opioids had 4.78 times greater odds of becoming hypo-
gonadal than did men on short-acting opioids [95% confidence
interval (CI), 1.51-15.07; P=0.008]. Body mass index was also
significantly associated with hypogonadism (odds ratio, 1.13; 95%
CI, 1.03-1.24; P=0.006), whereas daily dose was not (odds ratio,
1.02; 95% CI, 0.99-1.05; P=0.29).
Conclusions: Among a contemporary sample of men receiving
chronic daily opioids, we found a high prevalence of hypogonadism
associated with duration of action, but not with total daily dose of
the opioid.
Key Words: opioid, chronic pain, long-acting opioid, short-acting
opioid, hypogonadism, testosterone, opioid risk
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Hypogonadism or low testosterone is a clinical entitythat has effects on the health and well-being of men in
multiple ways. Low testosterone is associated with
decreases in muscle mass, cognition, mood, and libido, and
a general quality of life.1 In our clinical experience the
problem of low testosterone can compound the already
challenging task of treating men with chronic pain. In
addition, testosterone is necessary for the maintenance of
bone density and it is common for men with chronically
low testosterone to develop osteopenia or osteoporosis.2,3
Elucidating the relationship between opioid use and low
testosterone is critical to achieving the safest and most
efficacious use of opioids in men with chronic pain.
It has been documented since the 1970s that opioid use
is linked to hypogonadism among men being treated for
heroin addiction with methadone as well as men using
heroin.1,4,5 More recent studies have evaluated men with
chronic pain on long-acting opioids (LAO) such as meth-
adone, long-acting formulations of morphine or oxy-
codone, or intrathecal formulations.6–8 Data consistently
demonstrate a high rate of hypogonadism in these men,
ranging from 54% to 86% whether they were receiving
opioids for chronic pain, illicit use such as with heroin, or
treatment of chemical dependency/addiction.8–12 This effect
happens quickly,13 can be profound,1 and appears to be
reversible.14,15 No studies to date have examined the effect
of short-acting or immediate-release opioids on testoster-
one levels in men.
Although there may be a relationship between total
daily dose of opioid and hypogonadism,5,11,15 all studies to
date have had inadequate statistical power to address this
question definitively. There are studies that suggest that
not all opioids are equally suppressive. Two small studies of
men using methadone or buprenorphine for treatment of
heroin addiction have shown that methadone has a greater
suppressive effect on testosterone than buprenorphine.16,17
Whether this is due to specific characteristics of the indi-
vidual drugs, their duration of action or the dosages at
which they are used is unclear. To our knowledge, there has
not been a previous evaluation of the association of
hypogonadism and specific opioids, duration of action, or
total daily opioid dose.
PATIENTS AND METHODS
Study Population
This was a retrospective cohort study of men between
the age of 18 and 80 years referred to the Santa Rosa
Chronic Pain Clinic within Kaiser Permanente, Northern
California (KPNC) for evaluation between January 2009
and June 2010. All men carried a diagnosis of chronic pain,
defined as pain lasting more than 3 months without any
etiology that allowed for a definitive or curative treatment.
Chronic pain conditions in this cohort consisted primarily
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of low back pain and myofascial pain but also included
failed back syndrome, spinal stenosis, chronic headaches,
peripheral neuropathy, rheumatoid arthritis, and ankylos-
ing spondylitis. Men with previously diagnosed hypo-
gonadism, a history of prostate cancer, or those with a
known endocrine disorder, aside from stable, treated
hypothyroidism, were excluded. All men were on a stable
dose of daily opioid defined as an unchanging opioid dose
with at least 3 prescriptions of 30-day supply purchased at a
KPNC pharmacy in the preceding 100 days. A urine tox-
icology screen to ensure compliance with pain medications
and an AM serum total testosterone level (TT) were
obtained in all men, as is our usual practice.
Of 91 men tested, 3 men receiving intrathecal opioids
were excluded because of an inability to reliably calculate a
24-hour morphine-standardized equivalent dose (MSE) for
them; of these 3 men 2 had TT levels <250 ng/dL. Also
excluded was 1 patient who admitted to using opioids that
were not being prescribed for him which made it impossible
to calculate his daily MSE. There were 5 men on “rare”
opioids who were also excluded from analysis. A rare
opioid in this case was defined as a drug or formulation that
was being used by only 1 person in the study. It was felt that
anonymity could not be assured for these patients if they
were included in the results. One man with low TT was
found to have hypogonadism based on primary gonadal
failure, and he was also eliminated from analysis. The total
number of men included in this analysis was 81. Electronic
data maintained in KPNC databases on outpatient and
inpatient diagnoses and procedures as well as ambulatory
pharmacy and laboratory utilization were collected on all
study patients.
All patients with a low TT level were offered a complete
endocrine evaluation to exclude other causes of hypogonad-
ism. The endocrine evaluation included electrolytes, renal
function, liver function creatinine, lipids, follicle stimulating
hormone, luteinizing hormone (LH), prostate specific anti-
gen, thyroid stimulating hormone, thyroxine (T4), iron, total
iron binding capacity, prolactin, a repeat TT, bone densi-
tometry, and an MRI of the pituitary.
All laboratory studies were performed at the KPNC
Regional Laboratory in Richmond, California. All labo-
ratory tests and studies were performed as standard practices
in coordination with our Department of Endocrinology. The
KPNC Region Institutional Review Board approved this
study with waiver of signed consent.
Baseline Characteristics
For each patient, the characteristics collected included
age, body mass index [BMI (kg/m2)18], specific opioid
therapy, total daily MSE, and duration of action. The total
daily MSE was calculated using the globalrph.com algo-
rithm as well as methods previously described by Pereira
et al.19 TT levels were obtained on each man as is recom-
mended by the Endocrine Society.20,21 Hypogonadism was
defined for all men as a TT level r250 ng/dL. All labo-
ratory measurements were obtained before 10 AM.
For the purpose of this study, opioids were defined as
either LAO or short-acting opioid (SAO) based on their
duration of action. LAOs are generally formulated to
provide more stable serum drug levels or provide analgesia
for an extended period of time, generally longer than 8
hours. Some medications such as methadone are inherently
pharmacologically long acting. However, some SAOs when
formulated as controlled-release or sustained-release
behave like LAOs. The fentanyl patch was included as an
LAO due to its formulation, which allows it to provide 72
hours of constant drug delivery per patch. SAOs by con-
trast are characterized by a rapid increase and decrease in
serum levels and a duration of analgesia of <6 hours.
Men who were on both an LAO and an SAO were
included in the LAO group only and their total daily MSE
was calculated based upon both medications. Men who
were on 2 different opioids that were both short acting were
included in the specific drug group corresponding to the
larger dose; their total daily MSE was calculated based on
the MSE of both of their SAOs. No men in this study were
on 2 different LAOs.
Buprenorphine
Eight patients in our cohort were on sublingual
buprenorphine, which is currently approved for treatment
of chemical dependency. All of these patients had chronic
pain and were opioid dependant before placement on
buprenorphine. In all cases either the patient self-identified
a concern with opioid use, or a decision between patient
and physician was made that buprenorphine would be an
appropriate choice given the patient’s use patterns, which
included escalating opioid doses, inability to control their
use, or rapidly decreasing efficacy of opioid medications.
Although these patients meet the criteria for chemical
dependency, this medication also provides highly effective
analgesia.
Laboratory Evaluations
TT was determined using Siemens Immulite 2000
Testosterone assay. (CV 9.6% at 149 ng/dL and 11.1% at
521 ng/dL).
Statistical Analyses
The association between hypogonadism and the dura-
tion of action of opioid as well as the potential confounders
age, BMI, and MSE was evaluated. We performed uni-
variate, bivariate, and multivariable analyses. Univariate
analyses were performed to assess the distribution of the
variables. We then performed bivariate analyses to assess the
association between hypogonadism and opioid duration of
action. Bivariate analyses were also performed to evaluate the
association between the potential confounders age, BMI,
MSE, and hypogonadism, as well as opioid duration of
action. We performed multivariable analyses to assess the
association between opioid duration of action and hypo-
gonadism controlling for age, BMI, and MSE.
Bivariate analysis of the dichotomous variable dura-
tion of action was performed using the w2 test. Bivariate
analyses of continuous variables were performed using the
Wilcoxon-Mann-Whitney nonparametric test, as the values
for age, BMI, and MSE were found to be not normally
distributed. The association of duration of action of opioids
with hypogonadism controlling for age, BMI, and MSE
was evaluated with logistic regression. There was inad-
equate power to assess the association between specific
opioids and hypogonadism in this study. Data management
and statistical analyses were performed using SAS version
9.13 (SAS Institute Inc., Cary, NC).
RESULTS
The study population consisted of a total of 81
patients who were between the age of 26 and 79 years
(median/mean age, 51 y) at the time of their first visit to our
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chronic pain department. The median BMI of this pop-
ulation was 29 kg/m2 and the mean was 31 kg/m2.
Forty-six patients (56.8%) were determined to be
hypogonadal, and 35 (43.2%) were not. The characteristics
of hypogonadal and nonhypogonadal men are described
in Table 1. Hypogonadal men had a higher median BMI
than nonhypogonadal men (P<0.001). There was no sig-
nificant difference in age between the 2 groups. Men who
were hypogonadal were on a higher median MSE of opioid
(median, 105mg/mean, 259mg) than men who were not
hypogonadal (median, 30mg/mean, 86mg; P<0.001).
Opioids by duration of action as well as percentage of
hypogonadal patients by opioid regimens are described
in Table 2.
A significantly higher proportion of men on LAOs (34/
46, 74%) were hypogonadal compared with those on SAOs
(12/35, 34%, P<0.001). Characteristics of study patients by
duration of action of opioid are shown in Table 3. There were
no significant differences in age or BMI between the 2 groups.
Patients on SAOs had a lower median and mean MSE
(medianMSE, 30mg; meanMSE, 40mg) than those on LAOs
(median MSE, 135mg; mean MSE, 295mg; P<0.001). Men
on SAOs had a higher median and mean TT level than men on
LAOs (SAO: median, 283ng/dL; mean, 315ng/dL vs. LAO:
median, 126ng/dL; mean, 169ng/dL; P<0.001).
The association of duration of action with hypo-
gonadism controlling for MSE and BMI was evaluated
using logistic regression (Table 4). When controlling for
MSE and BMI, patients on a regimen of LAOs had 4.78
times greater odds of being hypogonadal than did patients
on a regimen of SAOs [95% confidence interval (CI), 1.51-
15.07; P=0.008]. The CI for duration of action is wide, but
the effect is also large. When controlling for dosage as well
as duration of action of opioid, BMI was found to be sig-
nificant. For every unit increase of BMI, patients had
additional 13% higher odds of being hypogonadal. Dose
was adjusted to reflect 10mg of MSE. In this model for
every 10mg increase in MSE, patients had an additional
2% greater chance of being hypogonadal. MSE, however,
was not significantly associated with hypogonadism (95%
CI, 0.99-1.05; P=0.29). Age was not significantly asso-
ciated with hypogonadism in the bivariate analyses and was
therefore not included as a dependent variable in the
logistic regression.
The possibility of duration of action affecting hypo-
gonadism differently depending on dosage was considered.
We included the product of duration of action and MSE as
an independent variable to assess whether or not duration
of action behaves differently as MSE increased. We found
that this interaction term was not significantly associated
with hypogonadism.
DISCUSSION
Although this cohort study confirms a 74% incidence
of hypogonadism for men on LAOs, the incidence of
hypogonadism is significantly lower (34%) for men main-
tained on SAOs. The distribution of daily MSE differs
according to duration of action. Patients on SAOs were
generally on lower doses, <100mg of MSE daily. This may
be due to the dose-limiting acetaminophen contained in the
most commonly prescribed SAOs containing hydrocodone
and oxycodone. The men on LAOs by contrast had no
dose-limiting constraints. In our clinical experience, men on
LAOs tend to escalate their MSE over time, possibly due to
increased medication tolerance. It may be also that pain
thresholds drop and opioids are less effective in the context
of low testosterone.22 In this study it was imperative to
control for total daily MSE when assessing the association
between duration of action and hypogonadism in our
logistic regression. We found that duration of action was
associated with hypogonadism, and MSE was not; addi-
tional studies on larger sample sizes are needed to further
assess this relationship.
Animal studies have shown that opioids exert their
effect on the testosterone primarily through inhibition of
TABLE 1. Characteristics of Hypogonadal and Nonhypogonadal Men With Long-term use of Opioids
BMI (kg/m2) Age (y) MSE
N Mean Range Mean Range Mean Range
TTZ250ng/dL 46 32.4 17.4-47.4 53 26-79 259 15-2400
TT<250 ng/dL 35 28.3 17.7-58.3 51 25-71 86 5-1080
P — 0.0007 0.4 <0.0001
Analyses performed using the Wilcoxon-Mann-Whitney nonparametric test.
BMI indicates body mass index; MSE, morphine-standardized equivalent dose (mg); TT, serum AM total testosterone.
TABLE 2. Hypogonadism by Opioid
TT
Opioids Duration of Action Median Mean No. Patients (% of Total) No. Hypogonadal (% Hypogonadal)
Buprenorphine LAO 286 256 8 (9.9%) 3 (37.5%)
Fentanyl LAO 129 193 4 (4.9%) 3 (75.0%)
Methadone LAO 110 150 14 (17.3%) 11 (78.6%)
Morphine CR LAO 127 150 12 (14.8%) 10 (83.3%)
Oxycodone LAO 109 134 8 (9.9%) 7 (87.5%)
Oxycodone IR SAO 237 286 10 (12.3%) 5 (50.0%)
Hydrocodone SAO 293 326 25 (30.9%) 7 (28.0%)
CR indicates controlled-release; IR, immediate-release; LAO, long-acting opioids; SAO, short-acting opioids; TT, serum AM total testosterone.
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pulsatile GnRH, which leads to loss of pulsatile LH release
and in turn lower testosterone. There is a high concordance
between pulsatile GnRH and LH secretion. One mecha-
nism that could explain the greater suppressive effects of
LAOs compared with SAOs may stem from the relatively
more stable serum drug levels achieved with LAOs. There
may be a threshold serum drug level that causes GnRH
suppression, and both LAOs and SAOs may acutely cause
this suppression. With SAO use serum drug levels should
vary more throughout a 24-hour cycle. As serum drug levels
fall, GnRH suppression may cease leading to LH produc-
tion and testosterone. This intermittent GnRH and LH
suppression may allow enough testosterone to be produced
to keep men in the clinically normal range. There are to
date no studies that examine this specific mechanism with
respect to exogenous opioids of differing durations of
actions in humans; however, there are some small amounts
of supporting data from animal studies. A single-dose
morphine has been shown to reduce testosterone levels in
rats after 4 hours; this effect is predominately reversed after
24 hours.23 Opioid agonists have been shown to change
GnRH and LH levels in humans and animals acutely, and
this effect is reversed by administration of the opioid
antagonist naloxone.24–27
LAOs have long been believed to offer less risk of
abuse because the central effect or “high” that can lead to
addictive behaviors is at least in part a result of rapidly
changing serum levels rather than the absolute serum con-
centration. However, there is no evidence of decreased
abuse potential with LAO compared with SAO.28,29
Randomized controlled trials comparing efficacy of LAO
relative to SAO have also failed to show superiority in
terms of pain control.30–33 To our knowledge, our study is
the first to examine a risk directly related to the duration of
action of a medication. Our results may raise the question
of whether the risks associated with LAOs are less favor-
able than those associated with SAOs. More studies would
be required to further elucidate this mechanism.
Buprenorphine
It should be noted that buprenorphine was counted as
an LAO in this study, but previous studies suggest that it is
associated with significantly less hypogonadism than
methadone.16,17 Thirty-eight percent of men on buprenor-
phine were found to be hypogonadal, but our sample size
was too small to evaluate statistically the association
between each drug and hypogonadism. This proportion,
however, is consistent with the crude prevalence of hypo-
gonadism in the general population reported in 1 recent
study.34 An evaluation with a larger sample size could
perhaps clarify the association between risk of hypo-
gonadism and the use of buprenorphine.
Strengths and Limitations
A strength of this study was that it was conducted in
KPNC, a large integrated health care delivery system pro-
viding care for more than 3.2 million members in the San
Francisco and greater Bay Area. KPNC’s electronic medi-
cal record system and robust laboratory, pharmacy, hos-
pital, and medical office diagnosis databases allow for more
complete data capture. Although our cohort size of 81 is
small, it is one of the largest reported to date of men
receiving chronic, daily opioid therapy. A limitation of our
study was that the sample size of our cohort was too small
to allow us to assess potential differences in rates of
hypogonadism between specific drugs. In addition, the men
in this study were all referred to our tertiary pain clinic,
presumably for increasing pain, decreasing efficacy of
treatment, or general failure to improve, and therefore may
not be representative of the population of chronic pain
patients in general. The symptoms of hypogonadism
including increased pain, depressed mood, and a general
decreased response to opioid treatment may have con-
tributed to the referral in the first place.
Although we used urine toxicology screening and
pharmacy records to help ensure compliance with the
medications being prescribed, we could not guarantee that
each man was taking his opioid as prescribed. We have no
data on the relationship between time of dosing and time of
TT measurement.
Additional variables not evaluated in this study but
known to be associated with low testosterone in men
include atherosclerosis, metabolic syndrome, dyslipidemia,
hypertension, and type 2 diabetes. What is not known,
however, is whether these morbidities are contributory to
low testosterone levels in men or are a result of low tes-
tosterone levels.35–38 Indeed the relationship may be bidir-
ectional, implying both that these diseases contribute to
lower testosterone levels in men and that low testosterone
TABLE 3. Characteristics by Duration of Action of Opioid
Median/Mean
Duration of Action N MSE (mg) BMI (kg/m2) Age (y) TT (ng/dL)
LAO 46 135/295 30/30 52/52 126/169
SAO 35 30/40 28/31 52/53 283/315
P — <0.0001 0.65 0.64 <0.001
Analyses performed using the Wilcoxon-Mann-Whitney nonparametric test.
BMI indicates body mass index; LAO, long-acting opioids; MSE, morphine-standardized equivalent dose in mg; SAO, short-acting opioids; TT, serum AM
total testosterone.
TABLE 4. Association of Duration of Action With Hypogonadism
Controlling for Dosage and BMI




MSE 1.02 0.99-1.05 0.29
BMI (kg/m2) 1.13 1.03-1.24 0.006
Analysis performed using logistic regression.
BMI indicates body mass index; LAO, long-acting opioids; MSE,
morphine-standardized equivalent dose (mg); SAO, short-acting opioids.
Rubinstein et al Clin J Pain  Volume 00, Number 00, ’’ 2013
4 | www.clinicalpain.com r 2013 Lippincott Williams & Wilkins
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
levels may aggravate or contribute to the development of
the diseases.
With a sample size of 81 patients it was not possible to
include each of these factors in the model. A larger study is
needed to further define the relationship between these
morbidities and testosterone levels.
CONCLUSIONS
LAOs have been the mainstay of opioid treatment for
chronic pain for the last decade. It has been estimated that
4.3 million Americans use opioids on a daily basis.39 To
date no study has shown a difference in safety or efficacy
between LAOs and SAOs. This is the first study to suggest
that independent of MSE, daily use of LAOs is associated
with hypogonadism compared with daily use of SAOs.
Future studies both prospective and epidemiologic that can
control for other causes of hypogonadism are needed to
further define the relationship between duration of action
and testosterone suppression in men who consume opioids
daily for chronic pain.
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